Cara E. Brocklehurst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cara E. Brocklehurst has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Marco Palmieri
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
5 shared publicationsAlexander N. Marziale
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
3 shared publications- Corentin Bon
Department of Chemistry, University of Basel, St. Johanns-Ring 19, Basel 4056, Switzerland
3 shared publications - Daniel J. Gosling
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
3 shared publications - Fabio Lima
Global Discovery Chemistry Novartis Biomedical Research Basel 4056 Switzerland
3 shared publications Holly Davis
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland
3 shared publications
Latest Publications
- 4 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7782-7816
Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter
The interaction of transcriptional enhanced associate domain (TEAD) and transcriptional coactivator yes-associated protein (YAP) mediates oncogenic functions downstream of the Hippo pathway. In this report, we outline our efforts to find a potent inhibitor of this protein–protein interaction with suitable properties for clinical evaluation. We detail the medicinal chemistry program that led to the discovery of IAG933, an inhibitor with a balanced ADME profile, enabling its evaluation as a potential treatment option in clinical settings.
- 4 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7782-7816
Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter
The interaction of transcriptional enhanced associate domain (TEAD) and transcriptional coactivator yes-associated protein (YAP) mediates oncogenic functions downstream of the Hippo pathway. In this report, we outline our efforts to find a potent inhibitor of this protein–protein interaction with suitable properties for clinical evaluation. We detail the medicinal chemistry program that led to the discovery of IAG933, an inhibitor with a balanced ADME profile, enabling its evaluation as a potential treatment option in clinical settings.
- 17 September 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (39) , 26759-26765
Oxadiazolines as Photoreleasable Labels for Drug Target Identification
Photoaffinity labeling is a widely used technique for studying ligand-protein and protein-protein interactions. Traditional photoaffinity labels utilize nonspecific C-H bond insertion reactions mediated by a highly reactive intermediate. Despite being the most widely used photoaffinity labels, diazirines exhibit limited compatibility with downstream organic reactions and suffer from storage stability concerns. This study introduces oxadiazolines as innovative and complementary photoactivatable labels for addition to the toolbox and demonstrates their application in vitro and through in cellulo labeling experiments. Oxadiazolines can be easily synthesized from ketone moieties and cleaved with 302-330 nm light to cleanly liberate a diazo reactive moiety that can covalently modify nucleophilic amino acid residues. Notably, oxadiazolines are compatible with various organic reaction conditions and functional groups, allowing for the exploration of a large chemical space. Several known inhibitors featuring the oxadiazoline functionality were prepared without affecting their binding affinity. Furthermore, we confirmed the ability of oxadiazolines to form covalent bonds with proteins upon UV-irradiation, both in vitro and in cellulo, yielding comparable results to those of the matched diazirine compounds.
- 17 September 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (39) , 26759-26765
Oxadiazolines as Photoreleasable Labels for Drug Target Identification
Photoaffinity labeling is a widely used technique for studying ligand-protein and protein-protein interactions. Traditional photoaffinity labels utilize nonspecific C-H bond insertion reactions mediated by a highly reactive intermediate. Despite being the most widely used photoaffinity labels, diazirines exhibit limited compatibility with downstream organic reactions and suffer from storage stability concerns. This study introduces oxadiazolines as innovative and complementary photoactivatable labels for addition to the toolbox and demonstrates their application in vitro and through in cellulo labeling experiments. Oxadiazolines can be easily synthesized from ketone moieties and cleaved with 302-330 nm light to cleanly liberate a diazo reactive moiety that can covalently modify nucleophilic amino acid residues. Notably, oxadiazolines are compatible with various organic reaction conditions and functional groups, allowing for the exploration of a large chemical space. Several known inhibitors featuring the oxadiazoline functionality were prepared without affecting their binding affinity. Furthermore, we confirmed the ability of oxadiazolines to form covalent bonds with proteins upon UV-irradiation, both in vitro and in cellulo, yielding comparable results to those of the matched diazirine compounds.
- 12 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 5111-5112
Correction to “MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery”
- 12 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 5111-5112
Correction to “MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery”
- 25 January 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (3) , 2118-2128
MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery
We herein describe the development and application of a modular technology platform which incorporates recent advances in plate-based microscale chemistry, automated purification, in situ quantification, and robotic liquid handling to enable rapid access to high-quality chemical matter already formatted for assays. In using microscale chemistry and thus consuming minimal chemical matter, the platform is not only efficient but also follows green chemistry principles. By reorienting existing high-throughput assay technology, the platform can generate a full package of relevant data on each set of compounds in every learning cycle. The multiparameter exploration of chemical and property space is hereby driven by active learning models. The enhanced compound optimization process is generating knowledge for drug discovery projects in a time frame never before possible.
- 25 January 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (3) , 2118-2128
MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery
We herein describe the development and application of a modular technology platform which incorporates recent advances in plate-based microscale chemistry, automated purification, in situ quantification, and robotic liquid handling to enable rapid access to high-quality chemical matter already formatted for assays. In using microscale chemistry and thus consuming minimal chemical matter, the platform is not only efficient but also follows green chemistry principles. By reorienting existing high-throughput assay technology, the platform can generate a full package of relevant data on each set of compounds in every learning cycle. The multiparameter exploration of chemical and property space is hereby driven by active learning models. The enhanced compound optimization process is generating knowledge for drug discovery projects in a time frame never before possible.
- Open Access
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadj2314
High-throughput synthesis provides data for predicting molecular properties and reaction success
The generation of attractive scaffolds for drug discovery efforts requires the expeditious synthesis of diverse analogues from readily available building blocks. This endeavor necessitates a trade-off between diversity and ease of access and is further complicated by uncertainty about the synthesizability and pharmacokinetic properties of the resulting compounds. Here, we document a platform that leverages photocatalytic N-heterocycle synthesis, high-throughput experimentation, automated purification, and physicochemical assays on 1152 discrete reactions. Together, the data generated allow rational predictions of the synthesizability of stereochemically diverse C-substituted N-saturated heterocycles with deep learning and reveal unexpected trends on the relationship between structure and properties. This study exemplifies how organic chemists can exploit state-of-the-art technologies to markedly increase throughput and confidence in the preparation of drug-like molecules.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (43) , eadj2314
Open AccessHigh-throughput synthesis provides data for predicting molecular properties and reaction success
The generation of attractive scaffolds for drug discovery efforts requires the expeditious synthesis of diverse analogues from readily available building blocks. This endeavor necessitates a trade-off between diversity and ease of access and is further complicated by uncertainty about the synthesizability and pharmacokinetic properties of the resulting compounds. Here, we document a platform that leverages photocatalytic N-heterocycle synthesis, high-throughput experimentation, automated purification, and physicochemical assays on 1152 discrete reactions. Together, the data generated allow rational predictions of the synthesizability of stereochemically diverse C-substituted N-saturated heterocycles with deep learning and reveal unexpected trends on the relationship between structure and properties. This study exemplifies how organic chemists can exploit state-of-the-art technologies to markedly increase throughput and confidence in the preparation of drug-like molecules.
- Open Access
- 28 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (40) , 11261-11266
Calculation-assisted regioselective functionalization of the imidazo[1,2-a]pyrazine scaffold via zinc and magnesium organometallic intermediates
Theoretical calculations, such as pKa-determinations, enabled the design of methods for the selective functionalization of the underexplored 6-chloroimidazo[1,2-a]pyrazine using readily available TMP-bases and organometallic reagents.
- 28 September 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (40) , 11261-11266
Open AccessCalculation-assisted regioselective functionalization of the imidazo[1,2-a]pyrazine scaffold via zinc and magnesium organometallic intermediates
Theoretical calculations, such as pKa-determinations, enabled the design of methods for the selective functionalization of the underexplored 6-chloroimidazo[1,2-a]pyrazine using readily available TMP-bases and organometallic reagents.
- Open Access
- 27 July 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (36) , e202308379
Late‐Stage Aryl C−H Bond Cyclopropenylation with Cyclopropenium Cations
Herein, we disclose the first regio‐, site‐ and chemoselective late‐stage (hetero)aryl C−H bond cyclopropenylation with cyclopropenium cations (CPCs). The process is fast, operationally simple and shows an excellent functional group tolerance in densely‐functionalized drug molecules, natural products, agrochemicals and fluorescent dyes. Moreover, we discovered that the installation of the cyclopropene ring in drug molecules could not only be used to shield against metabolic instability but also as a synthetic tool to reach medicinally‐relevant sp3‐rich scaffolds exploiting the highly‐strained nature of the cyclopropene ring with known transformations.
- 27 July 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (36) , e202308379
Open AccessLate‐Stage Aryl C−H Bond Cyclopropenylation with Cyclopropenium Cations
Herein, we disclose the first regio‐, site‐ and chemoselective late‐stage (hetero)aryl C−H bond cyclopropenylation with cyclopropenium cations (CPCs). The process is fast, operationally simple and shows an excellent functional group tolerance in densely‐functionalized drug molecules, natural products, agrochemicals and fluorescent dyes. Moreover, we discovered that the installation of the cyclopropene ring in drug molecules could not only be used to shield against metabolic instability but also as a synthetic tool to reach medicinally‐relevant sp3‐rich scaffolds exploiting the highly‐strained nature of the cyclopropene ring with known transformations.
- Open Access
- 27 July 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (36)
Late‐Stage Aryl C−H Bond Cyclopropenylation with Cyclopropenium Cations
Herein, we disclose the first regio‐, site‐ and chemoselective late‐stage (hetero)aryl C−H bond cyclopropenylation with cyclopropenium cations (CPCs). The process is fast, operationally simple and shows an excellent functional group tolerance in densely‐functionalized drug molecules, natural products, agrochemicals and fluorescent dyes. Moreover, we discovered that the installation of the cyclopropene ring in drug molecules could not only be used to shield against metabolic instability but also as a synthetic tool to reach medicinally‐relevant sp3‐rich scaffolds exploiting the highly‐strained nature of the cyclopropene ring with known transformations.
- 27 July 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (36)
Open AccessLate‐Stage Aryl C−H Bond Cyclopropenylation with Cyclopropenium Cations
Herein, we disclose the first regio‐, site‐ and chemoselective late‐stage (hetero)aryl C−H bond cyclopropenylation with cyclopropenium cations (CPCs). The process is fast, operationally simple and shows an excellent functional group tolerance in densely‐functionalized drug molecules, natural products, agrochemicals and fluorescent dyes. Moreover, we discovered that the installation of the cyclopropene ring in drug molecules could not only be used to shield against metabolic instability but also as a synthetic tool to reach medicinally‐relevant sp3‐rich scaffolds exploiting the highly‐strained nature of the cyclopropene ring with known transformations.
- Open Access
- 24 August 2022
- Published by Elsevier in SLAS Technology
- Vol. 27 (6) , 350-360
Integrated and automated high-throughput purification of libraries on microscale
- 24 August 2022
- Published by Elsevier in SLAS Technology
- Vol. 27 (6) , 350-360
Open AccessIntegrated and automated high-throughput purification of libraries on microscale
- 28 September 2021
- Published by Springer Nature in Nature Chemistry
- Vol. 13 (10) , 928-930
Building bridges
- 28 September 2021
- Published by Springer Nature in Nature Chemistry
- Vol. 13 (10) , 928-930
Building bridges